News

The most complete picture yet is coming into focus of how antibodies produced in people who effectively fight off SARS-CoV-2 work to neutralize the part of the virus responsible for causing infection. In the journal Science, researchers at The University of Texas at Austin describe the finding, which represents good news for designing the next generation of vaccines to protect against variants of the virus or future emerging coronaviruses.

Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in Cell Reports, researchers from The University of Texas at Austin, Rensselaer Polytechnic Institute (RPI) and the Icahn School of Medicine at Mount Sinai showed that four drugs used to treat hepatitis C render remdesivir 10 times better at inhibiting the coronavirus in cell cultures.

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium. Scientists first discovered it in early December in the United Kingdom, where the highly contagious and more lethal variant is thought to have originated. The journal Emerging Infectious Diseases, which has published an early-release version of the study, provides evidence that the coronavirus variant B117 (501Y) had spread across the globe undetected for months when scientists discovered it.

When we get sick, we change our social interactions—we keep away from others and we don't share food. It turns out, humans aren't the only species to do it.

More effective antiviral treatments could be on the way after research from The University of Texas at Austin sheds new light on the COVID-19 antiviral drug remdesivir, the only treatment of its kind currently approved in the U.S. for the coronavirus.

The world's largest multidisciplinary scientific society has announced that Jason McLellan, a University of Texas at Austin associate professor in the Department of Molecular Biosciences, and Daniel Wrapp, a graduate student fellow, were among seven winners of this year's Golden Goose Award. Supported by members of Congress from both parties and a coalition of businesses, universities and scientific societies since 2012, the prize this year went to scientists "whose federally funded research has had a significant impact for the response and treatment of COVID-19."

With COVID-19 cases hitting new highs across the country, a new online tool can help families and school leaders estimate how many infected people are likely to show up at a school on a given day anywhere in the United States. The free, interactive dashboard was produced by The University of Texas at Austin COVID-19 Modeling Consortium.

A study involving more than 5,000 COVID-19 patients in Houston finds that the virus that causes the disease is accumulating genetic mutations, one of which may have made it more contagious. According to the paper published in the peer-reviewed journal mBIO, that mutation, called D614G, is located in the spike protein that pries open our cells for viral entry. It's the largest peer-reviewed study of SARS-CoV-2 genome sequences in one metropolitan region of the U.S. to date.

Construction workers have a much higher risk of becoming hospitalized with the novel coronavirus than non-construction workers, according to a new study from researchers with The University of Texas at Austin COVID-19 Modeling Consortium.